论文部分内容阅读
通过一系列动物模型,已经对IL-2基因修饰的瘤苗的免疫调节作用和肿瘤治疗效果进行了广泛研究,并且IL-2基因修饰的瘤苗已进入临床试用阶段。本研究表明,此种瘤苗分泌IL-2水平不同会直接影响其治疗效果。为了进行实验,作者制备了体外分泌21种不同水平IL-2(0.01～7500U/10~5细胞/天)M-3黑色素瘤细胞,此水平囊括了目前为止所有报道的IL-2基因转染瘤苗分泌IL-2的水平。给每只实验组小鼠皮下接种10~5个放射线灭活后的基因修饰的M-3细胞。对照组小鼠每只皮下接种相同数量的灭
Through a series of animal models, immunomodulatory effects and tumor therapeutic effects of IL-2 gene-modified tumor vaccines have been extensively studied, and IL-2 gene-modified tumor vaccines have entered a clinical trial phase. This study shows that different levels of IL-2 secreted by such tumors will directly affect the therapeutic effect. In order to carry out experiments, the authors prepared 21 different levels of IL-2 (0.01 to 7500 U/10~5 cells/day) M-3 melanoma cells secreted in vitro. This level includes all the reported IL-2 gene transfection so far. The tumor vaccine secretes IL-2 levels. Each experimental group of mice was inoculated subcutaneously with 10 to 5 radiation-activated genetically modified M-3 cells. Each mouse in the control group was inoculated subcutaneously with the same amount of extinction.